Search Result

Results for "

PD-L1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (221) 5-HT Receptor (2) Adrenergic Receptor (2) Akt (2) Apoptosis (17) Aryl Hydrocarbon Receptor (2) AUTACs (1) Autophagy (6) Bcr-Abl (1) Biochemical Assay Reagents (1) c-Fms (1) c-Kit (2) CD19 (1) CD28 (1) CD73 (1) CTLA-4 (5) Cytochrome P450 (4) Deubiquitinase (1) DGK (2) Discoidin Domain Receptor (2) Dopamine Receptor (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (3) EGFR (4) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) FLT3 (2) Fungal (3) GPR55 (1) GSK-3 (1) HBV (3) HDAC (5) HIF/HIF Prolyl-Hydroxylase (4) Histone Demethylase (3) HSP (3) IFNAR (2) IKK (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (1) Keap1-Nrf2 (1) LAG-3 (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (5) Liposome (1) LRRK2 (3) MAP4K (4) MMP (1) MNK (3) Monoamine Oxidase (8) NAMPT (1) Neurotensin Receptor (1) NF-κB (2) NOD-like Receptor (NLR) (1) PARP (2) Phosphatase (2) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (1) PROTAC Linkers (3) PROTACs (5) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (2) Reactive Oxygen Species (3) ROR (1) Src (1) STAT (6) STING (3) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (2) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (6) Trk Receptor (2) ULK (1) VEGFR (3) α-synuclein (3)
By Research Areas:	Cancer (247) Cardiovascular Disease (1) Endocrinology (2) Infection (13) Inflammation/Immunology (75) Metabolic Disease (1) Neurological Disease (18)
Click Chemistry:	DBCO (1) Azide (1)

304

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149830

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting *PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1* expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research ^[1].

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research ^[1].

HY-139781

PD-L1-IN-1	PD-1/PD-L1	Cancer
PD-L1-IN-1 is a potent *PD-L1* inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells ^[1].

HY-162973

PD-L1 ligand 1	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
PD-L1 ligand 1 is a PROTAC target protein ligand. PD-L1 ligand 1 can be used as a *PD-L1* degrader ^[1].

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-163958

PD-L1-IN-7	PD-1/PD-L1	Cancer
PD-L1-IN-7 (compound CB31) is an inhibitor of *PD-L1, which can induce PD-L1* internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC₅₀: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells ^[1].

HY-169363

PDL1 degrader-2	PD-1/PD-L1 Autophagy AUTACs	Cancer
PD-L1 degrader-2 (Compound B3) is an orally active AUTAC degrader, that degrades *PD-L1* through autophagy-lysosome pathway with a DC₅₀ of 0.5 μM. PD-L1 degrader-2 exhibits inhibitory activity against PD-1/PD-L1 interaction with an IC₅₀ of 22.8 nM. PD-L1 degrader-2 upregulates the expressions of Atg9b, Lamp1 and Mitf, and activates the autophagy lysosome system. PD-L1 degrader- exhibits antitumor efficacy in CT26 mouse model ^[1]. (Pink: autophagy-lysosome activator (HY-159894); Black: linker (HY-W015088); Blue: PD-L1 ligand (HY-169365))

HY-168530

PDL1 degrader-1	PD-1/PD-L1	Cancer
PDL1 degrader-1 (compound PMT-O9-1A) is a potent *PD-L1* degrader. PDL1 degrader-1 decreases the protein expression of PD-L1. PDL1 degrader-1 shows cytotoxicity. PDL1 degrader-1 shows anticancer activity ^[1].

HY-162357

PD-L1-IN-5	PD-1/PD-L1	Cancer
PD-L1-IN-5 (X22) is an orally active *PD-L1* inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo ^[1].

HY-162399

PD-L1-IN-6	PD-1/PD-L1 STAT	Inflammation/Immunology
PD-L1-IN-6 (Compound 16) is an orally active inhibitor for *PD-L1* expression in neutrophil by targeting STAT3 with K_D of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse ^[1].

HY-161677

PD-L1/CD-73-IN-1	PD-1/PD-L1 CD73	Inflammation/Immunology Cancer
PD-L1/CD-73-IN-1 (compound CC-5) is *PD-L1/CD73* inhibitor with IC₅₀ values of 6 nM and 0.773 μM to *PD-L1* and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro ^[1].

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research ^[1].

HY-P2474

*Human PD-L1* inhibitor I**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2478

*Human PD-L1* inhibitor V**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2478A

*Human PD-L1* inhibitor V TFA**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2564

*Human PD-L1* inhibitor III**	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P2470

*Human PD-L1* inhibitor II**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-163757

*PROTAC PD-L1* degrader-1**	PROTACs PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC PD-L1 degrader-1 is a CRBN-based *PD-L1-PROTAC* degrader with a notable PD-L1 protein degradation capability. PROTAC PD-L1 degrader-1 shows potent PD-L1 degradation in 4T1 cells with a DC₅₀ of 0.609 μM. PROTAC PD-L1 degrader-1 can be used for the study of breast cancer. (Blue: CRBN ligand (HY-150839), Black: linker; Pink: PD-L inhibitor (HY-19745)) ^[1].

HY-P2477

*Human PD-L1* inhibitor IV**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P5276

*Human membrane-bound PD-L1* polypeptide**	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-P990173

*Anti-Mouse/Rat/Human PD-L1* Antibody (368A.4H1)**	PD-1/PD-L1	Others
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.

HY-157811

*PD-1/PD-L1-IN-40*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

HY-134884

INCB086550 1 Publications Verification PD-1/PD-L1-IN-8	PD-1/PD-L1	Cancer
INCB086550 is a potent, oral, small-molecule *PD-L1* inhibitor with IC_50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research ^[1].

HY-145774

*PD-1/PD-L1-IN-23*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1* humanized mice ^[1].

HY-154869

*PD-1/PD-L1-IN-34*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment ^[1].

HY-152240

*PD-1/PD-L1-IN-29*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

HY-162343

*PD-1/PD-L1-IN-41*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM ^[1].

HY-P9919A

*Durvalumab (anti-PD-L1)* 5 Publications Verification MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

HY-103048

*PD-1/PD-L1-IN 3*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-103048A

*PD-1/PD-L1-IN 3 TFA*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P10217

*PD-1/PD-L1-IN-42*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-144447

*PD-1/PD-L1-IN-17*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

HY-144258

*PD-1/PD-L1-IN-14*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

HY-163307

*PD-1/PD-L1-IN-39*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

HY-159125

*PD-1/PD-L1-IN-47*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-47 (MolPort-001-742-690) is a PH-selective *PD-1/PD-L1* signaling pathway inhibitor with significant affinity for PD-L1 under acidic conditions and lower toxicity. PD-1/PD-L1-IN-47 can be used in the study of tumors ^[1].

HY-158052

*PD-1/PD-L1* antagonist 1**	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM ^[1].

HY-155959

*PD-1/PD-L1-IN-33*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

HY-144442

*PD-1/PD-L1-IN-15*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch ^[1].

HY-144443

*PD-1/PD-L1-IN-16*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

HY-168080

*PD-1/PD-L1-IN-51*	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity ^[1].

HY-132192

*PD-1/PD-L1-IN-9* 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-132192A

*PD-1/PD-L1-IN-9 hydrochloride* 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-116274

BMS-8	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 ^[1].

HY-163534

*PD-1/PD-L1-IN-43*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1. PD-1/PD-L1*-IN-43 can be used in anti-tumor studies ^[1].

HY-168081

*PD-1/PD-L1-IN-52*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between **PD-1 and PD-L1, with an IC₅₀** of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% ^[1].

HY-144746

*PD-1/PD-L1-IN-26*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases ^[1].

HY-129172

*PD-1/PD-L1-IN 5 TFA*	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

HY-153064

MAX-10181 PD-1/PD-L1-IN-30	PD-1/PD-L1	Cancer
MAX-10181 (PD-1/PD-L1-IN-30) is a *PD-1/PD-L1* binding inhibitor, with an IC₅₀ value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases ^[1].

HY-159892

*PD-1/PD-L1-IN-54*	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic *PD-1/PD-L1* inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 ^[1].

HY-131183

*PROTAC PD-1/PD-L1* degrader-1**	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner ^[1].

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library

1,608 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,608 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L031

Small Molecule Immuno-Oncology Compound Library

573 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 573 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L184

Anti-Gastric Cancer Compound Library

718 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 718 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L079

Anti-Blood Cancer Compound Library

3,056 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 3,056 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

5,860 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 5,860 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

656 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 656 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Type

HY-Y1738

Tetrakis(triphenylphosphine)palladium

Tetrakis(triphenylphosphine)palladium(0)

Biochemical Assay Reagents

Tetrakis(triphenylphosphine)palladium (Pd(PPhs)) series of cross-coupling catalysts can be used to construct an organic heterojunction solar cell model. Adding different amounts of Pd(PPhs) significantly affected free carrier generation, non-twin trap and surface trap-assisted recombination as well as bimolecular recombination and charge extraction, but the impact on the non-duplex recombination process was limited because the catalyst could not promote efficient Trap-assisted reorganization. The studied system is highly robust with the addition of a small amount of Pd(PPha) .

Cat. No.	Product Name	Target	Research Area

HY-P2474

*Human PD-L1* inhibitor I**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2478

*Human PD-L1* inhibitor V**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2470

*Human PD-L1* inhibitor II**	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-P2477

*Human PD-L1* inhibitor IV**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-103048A

*PD-1/PD-L1-IN 3 TFA*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P10375

BMS-986189	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-986189 is a macrocyclic peptide inhibitor of *PD-L1* (IC₅₀: 1.03 nM), and can be used for cancer research ^[1].

HY-P2478A

*Human PD-L1* inhibitor V TFA**	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P2564

*Human PD-L1* inhibitor III**	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P5276

*Human membrane-bound PD-L1* polypeptide**	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-P10217

*PD-1/PD-L1-IN-42*	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind *PD-L1* protein, significantly block the interaction between *PD-1* and *PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP*-1 can be used in cancer immunotherapy research ^[1].

HY-P10826

*PD-1/PD-L1* inhibitory peptide C8**	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model ^[1].

HY-P10439

CVRARTR	PD-1/PD-L1	Cancer
CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model ^[1].

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression ^[1].

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀?of 7.68?nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
PL120131 is a *PD-1/PD-L1* inhibitory peptide that can interfere with the interaction of *PD-1/PD-L1* by binding to *PD-1. PL120131 is capable of inhibiting the PD-1*-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs) ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1* expression.* [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes ^[1].

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable *hNTS1R* full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent ^[1].

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0242

Fraxinellone 3 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants Inflammation/Immunology Disease Research Fields	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a *PD-L1* inhibitor and inhibits *HIF-1α* protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 ^[1].

HY-N0596

Panaxadiol 20(R)-Panaxadiol	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (20(R)-Panaxadiol) is an orally active *HIF-1α/STAT3* inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities ^[1] .

HY-N3005

Britannin 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Inflammation/Immunology Disease Research Fields	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics ^[1] .

HY-N0460

1-Caffeoylquinic acid 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Source classification Phenols Polyphenols Plants Compositae Disease Research Fields Cancer	NF-κB
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.002 μM and binding energy of 1.50 Kcal/mol ^[1]. 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits *PD-1/PD-L1* interact .

HY-N12537

*PD-1/PD-L1-IN-38*	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	PD-1/PD-L1
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

HY-N12537A

*(2R,3S)-PD-1/PD-L1-IN-38*	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 ^[1].

HY-N0242R

Fraxinellone (Standard)	Structural Classification Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 ^[1].

HY-162614

Rogersonin E	Structural Classification Natural Products Microorganisms Source classification	PD-1/PD-L1
Rogersonin E can be isolated from an Ophiocordyceps-associated fungus, Clonostachys rogersoniana. Rogersonin E downregulates the expression of *PD-L1* protein in MDA-MB-231 and A549 cells ^[1].

HY-N0596R

Panaxadiol (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Source classification Plants Araliaceae	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities ^[1] .

HY-N0460R

1-Caffeoylquinic acid (Standard)	Phyllodium pulchellum (L.) Desv. Structural Classification Source classification Phenols Polyphenols Plants Compositae	NF-κB
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.002 μM and binding energy of 1.50 Kcal/mol ^[1]. 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits PD-1/PD-L1 interact .

Recombinant Proteins Recommended:

PD-L1
PD-L1

Species:	Human (8) Rhesus Macaque (2) Rat (2) Mouse (5) Cynomolgus (2) Canine (3)
Tag:	His (12) Tag Free (1) Avi (3) Fc (9) Flag (1)
Source:	HEK293 (21) CHO (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73361

	PD-L1 Protein, Human (HEK293) 4 Publications Verification Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free.

HY-P73364

	PD-L1 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Rat (HEK293, Fc) is 221 a.a., with molecular weight of ~63 kDa.

HY-P73365

	PD-L1 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of PD-L1 Protein, Rat (HEK293, His) is 221 a.a., with molecular weight of ~41.79 kDa.

HY-P73717

	PD-L1 Protein, Canine (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Canine	HEK293
	PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Canine (HEK293, Fc) is 218 a.a., with molecular weight of ~70-80 & 140-160 kDa, respectively.

HY-P73716

	PD-L1 Protein, Mouse (HEK293, His-Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

HY-P77347

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78633

	PD-L1 Protein, Canine (HEK293, His) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Canine	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Canine (HEK293, His) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Canine (HEK293, His) is 218 a.a., with molecular weight (glycosylation form) of 50 & 100 kDa, respectively.

HY-P70657

	PD-L1 Protein, Human (HEK293, mFc) Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, mFc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-mFc labeled tag.

HY-P77348

	PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rhesus Macaque	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Cynomolgus/Rhesus Macaque (Biotinylated, HEK293, His) is the recombinant Rhesus Macaque-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P703855

	PD-L1 Protein, Canine (218a.a, HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Canine	HEK293

HY-P70663

	PD-L1 Protein, Human (HEK293, Flag) Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293, Flag) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Flag labeled tag.

HY-P703080

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His-Avi) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P70672

	PD-L1 Protein, Human (221a.a, HEK293, Fc) Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1; Programmed Death Ligand 1; B7 Homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (221a.a, HEK293, Fc) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70721

	PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P77819

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is 220 a.a., with molecular weight of 45-60 kDa.

HY-P78192

	PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P70564

	PD-L1 Protein, Cynomolgus (HEK293, His) B7-H; B7H1; B7-H1; PDCD1L1; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, His) is 221 a.a., with molecular weight of 32-40 kDa.

HY-P71008

	PD-L1 Protein, Cynomolgus (HEK293, Fc) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PD-L1 Protein, Cynomolgus (HEK293, Fc) is 221 a.a., with molecular weight of ~73.0 kDa.

HY-P70632

	PD-L1 Protein, Mouse (HEK293, His) 1 Publications Verification Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PD-L1 Protein, Mouse (HEK293, His) is 220 a.a., with molecular weight of 38-58 kDa.

HY-P70633

	PD-L1 Protein, Mouse (HEK293, Fc) Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274;	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P7397

	PD-L1 Protein, Human (CHO, Fc) 1 Publications Verification rHuPD-L1, Fc Chimera; Programmed death ligand 1; CD274; B7-H1	Human	CHO
	PD-L1 Protein, Human (CHO, Fc) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7398

	PD-L1 Protein, Human (HEK293, His) rHuPD-L1, His; Programmed death ligand 1; CD274; B7-H1	Human	HEK293
	PD-L1 Protein, Human (HEK293, His) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-132559S

PD-166285-d4
PD-166285-d₄ is the deuterium labeled PD-166285[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80273

	PD-L1 Antibody	WB, IHC-P	Human
	PD-L1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 33 kDa, targeting to PD-L1. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-169392

D5B		DBCO
D5B is a potent and selective *PD-L1* inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PD-L1

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products